Castle Q3 revenue $23.5M (+54% YoY); guides FY21 $89-93M; acquiring Cernostics

CASTLE BIOSCIENCES INC

2021-Q3 EPS reported -$0.99 revenue$69,046,000

Q3 revenue $23.5M, up 54% vs $15.2M in Q3 2020; adjusted revenue $23.6M, up 71%.
Total test reports 7,727 (vs 4,779); DecisionDx-Melanoma 5,505 (+25%), DecisionDx-SCC 934.
Gross margin 77.9%; adjusted 80.9%; cash $363M as of Sept 30, 2021.
Signed definitive agreement to acquire Cernostics (TissueCypher BE test) to expand TAM by ~$1B; close expected by year-end 2021.
On track to meet raised FY21 revenue guidance of $89-93M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.